Aytu Biopharma (AYTU) Income from Discontinued Operations (2023 - 2025)

Aytu Biopharma (AYTU) has reported Income from Discontinued Operations for 3 consecutive years, with $62000.0 the latest figure, recorded in Q2 2025.

• On a quarterly basis, Income from Discontinued Operations rose 105.0% year-over-year to $62000.0 in Q2 2025; TTM through Mar 2026 was $62000.0, a 109.1% increase from a year earlier, with the FY2025 full-year figure at $620000.0, up 118.65% from the prior year.
• Income from Discontinued Operations was $62000.0 for Q2 2025 at Aytu Biopharma, up from $54000.0 in the prior quarter.
• Over five years, Income from Discontinued Operations peaked at $381000.0 in Q3 2024 and troughed at -$1.2 million in Q2 2024.
• A 3-year average of -$338000.0 and a median of -$272500.0 in 2024 frame the typical range for Income from Discontinued Operations.
• Across the five-year window, Income from Discontinued Operations jumped 158.89% in 2024 and soared 105.0% in 2025, its largest moves.
• Over 3 years, Income from Discontinued Operations stood at -$839000.0 in 2023, then jumped by 114.66% to $123000.0 in 2024, then tumbled by 49.59% to $62000.0 in 2025.
• The last three Income from Discontinued Operations figures came in at $62000.0 (Q2 2025), $54000.0 (Q1 2025), and $123000.0 (Q4 2024), per Business Quant data.